cortavance - Sökresultat

Europeiska unionen - engelska - EMA (European Medicines Agency)

heplisav b

dynavax gmbh - hepatitis b surface antigen - hepatitis b - vaccines - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations.it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Europeiska unionen - engelska - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaccines - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age.the use of qdenga should be in accordance with official recommendations.

Europeiska unionen - engelska - EMA (European Medicines Agency)

lymphoseek

navidea biopharmaceuticals europe ltd. - tilmanocept - radionuclide imaging - tumour detection, diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.radiolabelled lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.external imaging and intraoperative evaluation may be performed using a gamma detection device.